Propanc Biopharma Files S-1 for $1M Capital Raise, Faces Going Concern Doubt

TL;DR

**PPCB is a high-risk bet on an early-stage cancer drug with no revenue and a 'going concern' warning, making it a speculative play for aggressive traders.**

AI Summary

Propanc Biopharma, Inc. (PPCB), a development-stage healthcare company focused on cancer treatments, filed an S-1 to register 2,000,000 shares of common stock for resale by Hexstone Capital LLC. This registration stems from a Securities Purchase Agreement on October 7, 2025, which closed on November 4, 2025, where Propanc issued 100 shares of Series C Preferred Stock and a warrant for 9,900 additional Series C Preferred Stock to Hexstone Capital. The company received gross proceeds of approximately $1,000,000 from the initial closing, with potential for an additional $99,000,000 if the warrant is fully exercised at $10,000 per share. PPCB's lead product candidate, PRP, is in early-stage development for pancreatic, ovarian, and colorectal cancer. The company has no revenue-generating operations and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern, as explicitly stated in the filing. The common stock traded at $0.7498 per share on Nasdaq as of December 15, 2025.

Why It Matters

This S-1 filing signals Propanc Biopharma's attempt to secure capital through a private placement, but the resale of 2,000,000 shares by Hexstone Capital LLC could introduce significant selling pressure on PPCB's stock, potentially impacting existing investors. For employees, the company's 'going concern' warning highlights financial instability, while customers await the uncertain development of its lead cancer treatment, PRP. In the competitive biopharma landscape, PPCB's early-stage development and lack of revenue put it at a distinct disadvantage against more established players with robust pipelines and funding.

Risk Assessment

Risk Level: high — The company explicitly states it 'has no revenue generating operations and has an accumulated deficit,' along with 'negative cash flows from operations since inception,' which 'raises substantial doubt about its ability to continue as a going concern.' Furthermore, its lead product candidate, PRP, 'remains in the early stages of development and may never become commercially viable,' indicating significant clinical and commercialization risks.

Analyst Insight

Investors should approach PPCB with extreme caution due to the 'going concern' warning and early-stage product development. Consider this a highly speculative investment, and only allocate capital that you are prepared to lose entirely. Monitor the progress of PRP's clinical trials and any future financing activities closely.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

Not disclosed

total Debt

Not disclosed

net Income

Negative (accumulated deficit)

eps

N/A

gross Margin

N/A

cash Position

Not disclosed

revenue Growth

N/A

Key Numbers

• $1.0M — Gross proceeds from initial closing (Received from Hexstone Capital LLC for Series C Preferred Stock)
• $99.0M — Potential gross proceeds from warrant exercise (If the warrant for 9,900 Series C Preferred Stock is fully exercised at $10,000 per share)
• 2,000,000 — Shares of Common Stock registered for resale (Issuable upon conversion of Series C Preferred Stock held by Selling Stockholder)
• $0.7498 — Common Stock price (Last reported sale price on Nasdaq as of December 15, 2025)
• 100 — Initial Series C Preferred Stock shares (Issued to Hexstone Capital LLC)
• 9,900 — Series C Preferred Stock shares (Issuable upon exercise of the Warrant held by Hexstone Capital LLC)
• 4.99% — Beneficial ownership limitation (Initial conversion limitation for Series C Preferred Stock, adjustable to 9.99%)
• 9,500,000 — Required Reserve Amount (Initial number of Common Stock shares reserved for Series C Preferred Stock conversion)

Key Players & Entities

• Propanc Biopharma, Inc. (company) — Registrant and development-stage healthcare company
• Hexstone Capital LLC (company) — Selling Stockholder in the private placement
• James Nathanielsz (person) — Chief Executive Officer of Propanc Biopharma, Inc.
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• $1,000,000.00 (dollar_amount) — Gross proceeds received from the initial closing of the Securities Purchase Agreement
• $99,000,000.00 (dollar_amount) — Potential additional gross proceeds if the Warrant is exercised in full for cash
• $0.7498 (dollar_amount) — Last reported sale price of Common Stock on Nasdaq as of December 15, 2025
• $10,000 (dollar_amount) — Exercise price per share of Series C Preferred Stock for the Warrant
• Nasdaq (regulator) — Stock exchange where Common Stock is traded
• PRP (company) — Lead product candidate for cancer treatment

FAQ

Risk Factors

• Substantial doubt about going concern [high — financial]: The company has no revenue-generating operations and an accumulated deficit. This raises substantial doubt about its ability to continue as a going concern, as explicitly stated in the filing.
• Dependence on future financing [high — financial]: The company's ability to continue operations is dependent on its ability to secure additional funding. The S-1 filing is to register shares for resale by Hexstone Capital LLC, stemming from a recent financing round.
• Clinical trial and regulatory approval risks [high — regulatory]: Propanc's lead product candidate, PRP, is in early-stage development for pancreatic, ovarian, and colorectal cancer. Success is contingent on successful clinical trials and subsequent regulatory approvals, which are uncertain and time-consuming.
• Competition in cancer treatment market [medium — market]: The cancer treatment market is highly competitive, with numerous established pharmaceutical and biotechnology companies developing novel therapies. Propanc faces significant competition from companies with greater resources and established market presence.
• Reliance on key personnel [medium — operational]: As a development-stage company, Propanc's success is likely heavily reliant on its management team and scientific advisors. The loss of key personnel could significantly impact its research and development efforts.
• Dilution from preferred stock conversion [medium — financial]: The Series C Preferred Stock held by Hexstone Capital LLC is convertible into common stock. If fully exercised and converted, this could lead to significant dilution for existing common stockholders, especially given the large potential proceeds.

Industry Context

Propanc Biopharma operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on oncology. The industry is characterized by long development cycles, significant research and development costs, and stringent regulatory hurdles. Success hinges on groundbreaking scientific innovation, successful clinical trials, and securing substantial funding to navigate these challenges.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Propanc is subject to rigorous oversight by regulatory bodies like the FDA. The development and approval process for its lead candidate, PRP, involves extensive clinical trials to demonstrate safety and efficacy. Any delays, failures in trials, or adverse findings can significantly impact the company's prospects and require substantial additional investment.

What Investors Should Do

1. Assess the clinical trial progress and data for PRP.
2. Evaluate the company's cash burn rate and future financing needs.
3. Consider the significant dilution risk from Hexstone Capital's investment.
4. Monitor the competitive landscape in oncology drug development.

Key Dates

• 2025-10-07: Securities Purchase Agreement with Hexstone Capital LLC — Established the terms for the issuance of Series C Preferred Stock and a warrant, providing initial capital.
• 2025-11-04: Closing of initial financing with Hexstone Capital LLC — Propanc received $1.0M in gross proceeds, marking a crucial funding event for its development-stage operations.
• 2025-12-15: Common Stock last reported sale price — Indicates the current market valuation of the company's common stock at $0.7498 per share on Nasdaq.

Glossary

S-1 Filing

A registration statement filed with the SEC by companies that intend to offer securities to the public. It provides detailed information about the company's business, financial condition, and management. (This document is the primary source of information for the public offering and resale of Propanc's common stock.)

Series C Preferred Stock

A class of preferred stock with specific rights and preferences, often issued in private financing rounds. It is typically convertible into common stock. (Hexstone Capital LLC holds Series C Preferred Stock, which is convertible into common stock, forming the basis of the shares being registered for resale.)

Warrant

A financial instrument that gives the holder the right, but not the obligation, to buy a security (like stock) at a specified price (the exercise price) before a certain expiration date. (Hexstone Capital LLC received a warrant for additional Series C Preferred Stock, representing a potential future investment and significant dilution risk.)

Going Concern

An accounting term referring to the assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (The S-1 explicitly states substantial doubt about Propanc's ability to continue as a going concern due to its lack of revenue and accumulated deficit.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. It represents a negative retained earnings balance. (Propanc has an accumulated deficit, highlighting its lack of profitability and reliance on external funding.)

Selling Stockholder

An existing shareholder who is registering their shares for resale to the public through a company's S-1 filing. (Hexstone Capital LLC is the Selling Stockholder in this S-1 filing, aiming to resell up to 2,000,000 shares of common stock.)

Year-Over-Year Comparison

This analysis is based on an S-1 filing, which is typically an initial registration statement or a significant update. Without a prior S-1 filing for comparison, a direct year-over-year comparison of key metrics like revenue growth, margin changes, or new risks is not possible. However, the S-1 itself highlights the company's development-stage status, lack of revenue, and accumulated deficit, indicating a consistent financial profile of pre-revenue operations.

Key Financial Figures

• $0.001 — 0 shares of our common stock, par value $0.001 per share ("Common Stock"), by the sell
• $0.7498 — price of our Common Stock on Nasdaq was $0.7498 per share. We may amend or supplement
• $10,000 — Preferred Stock at an exercise price of $10,000 per share. The Company received gross
• $1,000,000.00 — s of approximately one million dollars ($1,000,000.00), not including expenses payable by the
• $10,000 b — ch share of Series C Preferred Stock of $10,000 by the conversion price. The conversion p
• $5.00 — lesser of the fixed conversion price of $5.00 per share or 85% of the of the lowest t
• $99,000,000.00 — roximately ninety nine million dollars ($99,000,000.00). The Company cannot predict when or if
• $250 m — public common equity float of more than $250 million, or (ii) we have annual revenues
• $100 million — ntly completed fiscal year of more than $100 million plus we have a public common equity flo
• $700 million — uity float or public float of more than $700 million. We also would not be eligible for stat
• $2,469 — n Stock at an average exercise price of $2,469 (see " Description of Our Securities "

Filing Documents

• forms-1.htm (S-1) — 4943KB
• ex5-1.htm (EX-5.1) — 18KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 30KB
• forms-1_001.jpg (GRAPHIC) — 9KB
• audit_001.jpg (GRAPHIC) — 30KB
• ex5-1_001.jpg (GRAPHIC) — 6KB
• 0001493152-25-029472.txt ( ) — 19899KB
• ppcb-20250930.xsd (EX-101.SCH) — 78KB
• ppcb-20250930_cal.xml (EX-101.CAL) — 86KB
• ppcb-20250930_def.xml (EX-101.DEF) — 468KB
• ppcb-20250930_lab.xml (EX-101.LAB) — 649KB
• ppcb-20250930_pre.xml (EX-101.PRE) — 568KB
• forms-1_htm.xml (XML) — 3229KB
• ex107_htm.xml (XML) — 4KB

Use of Proceeds

Use of Proceeds 31 Selling Stockholder 31 Plan of Distribution 32 Market for Our Common Stock and Related Stockholder Matters 33

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35

Business

Business 46 Management 78

Executive Compensation

Executive Compensation 86 Description of Our Securities 92 Shares Eligible for Future Sale 96 Material U.S. Federal Income Tax Considerations 97 Legal Matters 102 Experts 102 Where You Can Find More Information 102 Unless the context otherwise requires, we use the terms "we," "us," "Company," "Propanc Biopharma," and "our" to refer to Propanc Biopharma, Inc. and its subsidiaries. Solely for convenience, our trademarks and tradenames referred to in this prospectus, may appear without the or symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames. All other trademarks, service marks and trade names included or incorporated by reference into this prospectus, or the accompanying prospectus are the property of their respective owners. i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") pursuant to which the Selling Stockholder may, from time to time, offer and sell or otherwise dispose of the shares of our Common Stock covered by this prospectus. We will not receive any proceeds from the sale by the Selling Stockholder of the Shares offered by them described in this prospectus. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part. The prospectus supplement or post-effective amendment may add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. The registration statement we filed with the SEC, of which this prospectus forms a part, includes exhibits that provide more detail of the matters discusse

forward-looking statements will be achieved or occur at all. You should refer to the section titled "Risk factors" for a

forward-looking statements will be achieved or occur at all. You should refer to the section titled "Risk factors" for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. The Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act do not protect any forward-looking

View Full Filing

View this S-1 filing on SEC EDGAR